Syngene International Limited (SYNGENE.NS) Stock Competitors & Peer Comparison
See (SYNGENE.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYNGENE.NS | ₹437.40 | -1.25% | 175.7B | 45.75 | ₹9.56 | +0.29% |
| BIOCON.NS | ₹416.00 | -1.11% | 568.8B | 128.67 | ₹3.23 | +0.12% |
| BIOCON.BO | ₹416.75 | -1.17% | 568.4B | 133.27 | ₹3.13 | +0.12% |
| ANTHEM.NS | ₹761.40 | -1.00% | 427.7B | 145.03 | ₹5.25 | +0.26% |
| ONESOURCE.NS | ₹1,542.00 | -1.41% | 176.8B | -230.15 | -₹6.70 | N/A |
| SYNGENE.BO | ₹437.40 | -1.25% | 175.7B | 46.38 | ₹9.43 | +0.29% |
| CONCORDBIO.BO | ₹1,290.60 | +0.15% | 135.3B | 51.54 | ₹25.04 | +0.83% |
| CONCORDBIO.NS | ₹1,284.80 | -0.48% | 134.4B | 51.19 | ₹25.10 | +0.83% |
| BLUEJET.NS | ₹525.00 | +1.60% | 91.1B | 29.81 | ₹17.61 | +0.23% |
| BLUEJET.BO | ₹523.45 | +1.26% | 90.9B | 36.68 | ₹14.27 | +0.23% |
Stock Comparison
SYNGENE.NS vs BIOCON.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, BIOCON.NS has a market cap of 568.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while BIOCON.NS trades at ₹416.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas BIOCON.NS's P/E ratio is 128.67. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.NS's competition here
SYNGENE.NS vs BIOCON.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, BIOCON.BO has a market cap of 568.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while BIOCON.BO trades at ₹416.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas BIOCON.BO's P/E ratio is 133.27. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.BO's competition here
SYNGENE.NS vs ANTHEM.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, ANTHEM.NS has a market cap of 427.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while ANTHEM.NS trades at ₹761.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas ANTHEM.NS's P/E ratio is 145.03. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ANTHEM.NS's ROE of +0.22%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ANTHEM.NS's competition here
SYNGENE.NS vs ONESOURCE.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, ONESOURCE.NS has a market cap of 176.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while ONESOURCE.NS trades at ₹1,542.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas ONESOURCE.NS's P/E ratio is -230.15. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check ONESOURCE.NS's competition here
SYNGENE.NS vs SYNGENE.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SYNGENE.BO has a market cap of 175.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SYNGENE.BO trades at ₹437.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SYNGENE.BO's P/E ratio is 46.38. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SYNGENE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SYNGENE.BO's competition here
SYNGENE.NS vs CONCORDBIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, CONCORDBIO.BO has a market cap of 135.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while CONCORDBIO.BO trades at ₹1,290.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas CONCORDBIO.BO's P/E ratio is 51.54. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, SYNGENE.NS is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.BO's competition here
SYNGENE.NS vs CONCORDBIO.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, CONCORDBIO.NS has a market cap of 134.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while CONCORDBIO.NS trades at ₹1,284.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas CONCORDBIO.NS's P/E ratio is 51.19. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, SYNGENE.NS is less volatile compared to CONCORDBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.NS's competition here
SYNGENE.NS vs BLUEJET.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, BLUEJET.NS has a market cap of 91.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while BLUEJET.NS trades at ₹525.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas BLUEJET.NS's P/E ratio is 29.81. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.NS's ROE of +0.20%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.NS's competition here
SYNGENE.NS vs BLUEJET.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, BLUEJET.BO has a market cap of 90.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while BLUEJET.BO trades at ₹523.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas BLUEJET.BO's P/E ratio is 36.68. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.BO's ROE of +0.20%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.BO's competition here
SYNGENE.NS vs SUPRIYA.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SUPRIYA.BO has a market cap of 75.6B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SUPRIYA.BO trades at ₹939.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SUPRIYA.BO's P/E ratio is 36.13. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.BO's competition here
SYNGENE.NS vs SUPRIYA.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SUPRIYA.NS has a market cap of 75.6B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SUPRIYA.NS trades at ₹939.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SUPRIYA.NS's P/E ratio is 36.12. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.NS's competition here
SYNGENE.NS vs ZOTA.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, ZOTA.NS has a market cap of 42.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while ZOTA.NS trades at ₹1,388.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas ZOTA.NS's P/E ratio is -59.28. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, SYNGENE.NS is less volatile compared to ZOTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check ZOTA.NS's competition here
SYNGENE.NS vs PANACEABIO.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, PANACEABIO.NS has a market cap of 34B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while PANACEABIO.NS trades at ₹555.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas PANACEABIO.NS's P/E ratio is -300.11. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.NS's competition here
SYNGENE.NS vs PANACEABIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, PANACEABIO.BO has a market cap of 34B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while PANACEABIO.BO trades at ₹555.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas PANACEABIO.BO's P/E ratio is -300.15. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.BO's competition here
SYNGENE.NS vs DCAL.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, DCAL.NS has a market cap of 26.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while DCAL.NS trades at ₹170.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas DCAL.NS's P/E ratio is 22.73. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.NS's competition here
SYNGENE.NS vs DCAL.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, DCAL.BO has a market cap of 26.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while DCAL.BO trades at ₹170.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas DCAL.BO's P/E ratio is 22.82. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.BO's competition here
SYNGENE.NS vs TITANBIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, TITANBIO.BO has a market cap of 16.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while TITANBIO.BO trades at ₹397.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas TITANBIO.BO's P/E ratio is 40.76. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TITANBIO.BO's competition here
SYNGENE.NS vs FERMENTA.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, FERMENTA.BO has a market cap of 10.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while FERMENTA.BO trades at ₹364.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas FERMENTA.BO's P/E ratio is 11.33. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check FERMENTA.BO's competition here
SYNGENE.NS vs 3BBLACKBIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, 3BBLACKBIO.BO has a market cap of 9.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while 3BBLACKBIO.BO trades at ₹1,157.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas 3BBLACKBIO.BO's P/E ratio is 46.29. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, SYNGENE.NS is less volatile compared to 3BBLACKBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check 3BBLACKBIO.BO's competition here
SYNGENE.NS vs KILPEST.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, SYNGENE.NS is less volatile compared to KILPEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check KILPEST.BO's competition here
SYNGENE.NS vs HALEOSLABS.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, HALEOSLABS.NS has a market cap of 4.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while HALEOSLABS.NS trades at ₹1,417.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas HALEOSLABS.NS's P/E ratio is 24.74. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.NS's competition here
SYNGENE.NS vs SMSLIFE.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SMSLIFE.BO has a market cap of 4.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SMSLIFE.BO trades at ₹1,400.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SMSLIFE.BO's P/E ratio is 22.63. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.BO's competition here
SYNGENE.NS vs HALEOSLABS.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, HALEOSLABS.BO has a market cap of 4.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while HALEOSLABS.BO trades at ₹1,400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas HALEOSLABS.BO's P/E ratio is 24.48. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.BO's competition here
SYNGENE.NS vs TAKE.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, TAKE.NS has a market cap of 4.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while TAKE.NS trades at ₹27.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas TAKE.NS's P/E ratio is 37.70. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TAKE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.NS's competition here
SYNGENE.NS vs TAKE.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, TAKE.BO has a market cap of 4.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while TAKE.BO trades at ₹28.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas TAKE.BO's P/E ratio is 38.46. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TAKE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.BO's competition here
SYNGENE.NS vs SMSLIFE.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.NS's competition here
SYNGENE.NS vs LYKALABS.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, LYKALABS.BO has a market cap of 2.6B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while LYKALABS.BO trades at ₹71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas LYKALABS.BO's P/E ratio is -30.47. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, SYNGENE.NS is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.BO's competition here
SYNGENE.NS vs LYKALABS.NS Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, LYKALABS.NS has a market cap of 2.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while LYKALABS.NS trades at ₹71.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas LYKALABS.NS's P/E ratio is -25.27. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, SYNGENE.NS is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.NS's competition here
SYNGENE.NS vs ALFAVIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, ALFAVIO.BO has a market cap of 287.8M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while ALFAVIO.BO trades at ₹9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas ALFAVIO.BO's P/E ratio is -50.20. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ALFAVIO.BO's competition here
SYNGENE.NS vs TRABI.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, TRABI.BO has a market cap of 229.6M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while TRABI.BO trades at ₹3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas TRABI.BO's P/E ratio is -35.35. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TRABI.BO's competition here
SYNGENE.NS vs SAMSRITA.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SAMSRITA.BO has a market cap of 184.1M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SAMSRITA.BO trades at ₹12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SAMSRITA.BO's P/E ratio is -9.21. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SAMSRITA.BO's competition here
SYNGENE.NS vs VANTABIO.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, VANTABIO.BO has a market cap of 171.3M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while VANTABIO.BO trades at ₹24.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas VANTABIO.BO's P/E ratio is 160.60. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to VANTABIO.BO's ROE of -0.17%. Regarding short-term risk, SYNGENE.NS is more volatile compared to VANTABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check VANTABIO.BO's competition here
SYNGENE.NS vs STARSOURCE.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, STARSOURCE.BO has a market cap of 136.4M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while STARSOURCE.BO trades at ₹90.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas STARSOURCE.BO's P/E ratio is -1.15. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, SYNGENE.NS is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check STARSOURCE.BO's competition here
SYNGENE.NS vs GVBL.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, GVBL.BO has a market cap of 101.9M. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while GVBL.BO trades at ₹33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas GVBL.BO's P/E ratio is 333.60. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to GVBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check GVBL.BO's competition here
SYNGENE.NS vs SERVOTEACH.BO Comparison June 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 175.7B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, SYNGENE.NS is priced at ₹437.40, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 45.75, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SERVOTEACH.BO's competition here